Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th
Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Pam Garzone, their Chief Development Officer, will participate as a panelist at the Alliance for Cancer Gene Therapy (ACGT) Summit 2025. The event will take place on March 19-20, 2025, at the Alexandria Center for Life Science in New York City.
Dr. Garzone will join the Gynecologic and Breast Cancers panel on March 19th from 11:15 AM to 12:15 PM ET. The discussion will focus on advancements in cell and gene therapy, including Anixa's CAR-T therapy for ovarian cancer and its potential impact on gynecologic and breast cancers.
Dr. Amit Kumar, Chairman and CEO of Anixa, emphasized the importance of sharing insights at the summit to advance discussions on gene-based treatments for cancer. The ACGT Summit will gather leading physician scientists working on developing curative cell and gene therapies for solid tumor cancers.
Anixa Biosciences (NASDAQ: ANIX) ha annunciato che la Dr.ssa Pam Garzone, il loro Chief Development Officer, parteciperà come relatrice al Summit 2025 dell'Alliance for Cancer Gene Therapy (ACGT). L'evento si terrà il 19 e 20 marzo 2025, presso l'Alexandria Center for Life Science a New York City.
La Dr.ssa Garzone parteciperà al panel sui tumori ginecologici e al seno il 19 marzo dalle 11:15 alle 12:15 ET. La discussione si concentrerà sui progressi nella terapia cellulare e genica, inclusa la terapia CAR-T di Anixa per il cancro ovarico e il suo potenziale impatto sui tumori ginecologici e al seno.
Il Dr. Amit Kumar, Presidente e CEO di Anixa, ha sottolineato l'importanza di condividere informazioni durante il summit per far progredire le discussioni sui trattamenti basati sui geni per il cancro. Il Summit ACGT riunirà i principali scienziati medici che lavorano allo sviluppo di terapie cellulari e geniche curative per i tumori solidi.
Anixa Biosciences (NASDAQ: ANIX) anunció que la Dra. Pam Garzone, su Directora de Desarrollo, participará como panelista en el Summit 2025 de la Alliance for Cancer Gene Therapy (ACGT). El evento se llevará a cabo el 19 y 20 de marzo de 2025, en el Alexandria Center for Life Science en Nueva York.
La Dra. Garzone se unirá al panel de Cánceres Ginecológicos y de Mama el 19 de marzo de 11:15 AM a 12:15 PM ET. La discusión se centrará en los avances en terapia celular y génica, incluida la terapia CAR-T de Anixa para el cáncer de ovario y su posible impacto en los cánceres ginecológicos y de mama.
El Dr. Amit Kumar, Presidente y CEO de Anixa, enfatizó la importancia de compartir conocimientos en el summit para avanzar en las discusiones sobre tratamientos basados en genes para el cáncer. El Summit ACGT reunirá a destacados científicos médicos que trabajan en el desarrollo de terapias celulares y génicas curativas para los cánceres de tumores sólidos.
Anixa Biosciences (NASDAQ: ANIX)는 그들의 최고 개발 책임자인 Pam Garzone 박사가 2025년 암 유전자 치료 연합(ACGT) 정상 회담의 패널리스트로 참여할 것이라고 발표했습니다. 이 행사는 2025년 3월 19일부터 20일까지 뉴욕시의 알렉산드리아 생명과학 센터에서 열릴 예정입니다.
Garzone 박사는 3월 19일 오전 11시 15분부터 오후 12시 15분(ET)까지 여성암 및 유방암 패널에 참여할 것입니다. 이 논의는 세포 및 유전자 치료의 발전에 초점을 맞추며, Anixa의 난소암을 위한 CAR-T 치료법과 여성암 및 유방암에 미칠 잠재적 영향을 포함합니다.
Anixa의 회장 겸 CEO인 Amit Kumar 박사는 정상 회담에서 유전자 기반 암 치료에 대한 논의를 발전시키기 위해 통찰력을 공유하는 것이 중요하다고 강조했습니다. ACGT 정상 회담은 고형 종양 암을 위한 치유 세포 및 유전자 치료 개발에 힘쓰고 있는 주요 의학 과학자들을 모을 것입니다.
Anixa Biosciences (NASDAQ: ANIX) a annoncé que Dr. Pam Garzone, leur Directrice du Développement, participera en tant que panéliste au Sommet 2025 de l'Alliance for Cancer Gene Therapy (ACGT). L'événement aura lieu les 19 et 20 mars 2025, au Alexandria Center for Life Science à New York.
Dr. Garzone rejoindra le panel sur les cancers gynécologiques et du sein le 19 mars de 11h15 à 12h15 ET. La discussion portera sur les avancées en thérapie cellulaire et génique, y compris la thérapie CAR-T d'Anixa pour le cancer de l'ovaire et son impact potentiel sur les cancers gynécologiques et du sein.
Dr. Amit Kumar, Président et CEO d'Anixa, a souligné l'importance de partager des informations lors du sommet pour faire avancer les discussions sur les traitements basés sur les gènes pour le cancer. Le Sommet ACGT rassemblera des médecins chercheurs de premier plan travaillant sur le développement de thérapies cellulaires et géniques curatives pour les cancers des tumeurs solides.
Anixa Biosciences (NASDAQ: ANIX) gab bekannt, dass Dr. Pam Garzone, ihre Chief Development Officer, als Podiumsteilnehmerin am ACGT Summit 2025 der Alliance for Cancer Gene Therapy teilnehmen wird. Die Veranstaltung findet am 19. und 20. März 2025 im Alexandria Center for Life Science in New York City statt.
Dr. Garzone wird am 19. März von 11:15 bis 12:15 Uhr ET am Panel über gynäkologische und Brustkrebserkrankungen teilnehmen. Die Diskussion wird sich auf Fortschritte in der Zell- und Gentherapie konzentrieren, einschließlich Anixas CAR-T-Therapie für Eierstockkrebs und deren potenziellen Einfluss auf gynäkologische und Brustkrebserkrankungen.
Dr. Amit Kumar, Vorsitzender und CEO von Anixa, betonte die Bedeutung des Austauschs von Erkenntnissen auf dem Gipfel, um die Diskussionen über genbasierte Behandlungen für Krebs voranzutreiben. Der ACGT Summit wird führende medizinische Wissenschaftler versammeln, die an der Entwicklung heilender Zell- und Gentherapien für solide Tumorkrebserkrankungen arbeiten.
- None.
- None.
Dr. Garzone will join leading experts in the field to discuss advancements in cell and gene therapy, including Anixa's CAR-T therapy for ovarian cancer, and its potential impact on gynecologic and breast cancers. The panel is scheduled for Wednesday, March 19, 2025, from 11:15 AM – 12:15 PM ET.
Dr. Amit Kumar, Chairman and CEO of Anixa, stated, "We are pleased that Anixa and Dr. Garzone were invited to share insights at the ACGT Summit. Our discussions and contributions to the development of novel cancer therapies will help drive meaningful discussions on the future of gene-based treatments for gynecologic and breast cancers."
The Alliance for Cancer Gene Therapy Summit 2025 will bring together leading physician scientists advancing research to develop curative cell and gene therapies for solid tumor cancers.
For more information about the conference, visit Alliance for Gene Therapy Summit 2025.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-chief-development-officer-dr-pam-garzone-to-speak-at-the-alliance-for-cancer-gene-therapy-summit-2025-on-march-19th-302389363.html
SOURCE Anixa Biosciences, Inc.
FAQ
What will Anixa Biosciences present at the ACGT Summit 2025?
When and where is the Alliance for Cancer Gene Therapy Summit 2025 taking place?
What is the focus of Anixa's (ANIX) presentation at the ACGT Summit?
What time is Dr. Garzone's panel discussion at the ACGT Summit?
What types of cancer treatments will be discussed at the ACGT Summit 2025?
